Dr. Van Tine on Outcomes With Catequentinib in Synovial Sarcoma

Video

In Partnership With:

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Brian A. Van Tine, MD, PhD, associate professor, Department of Medicine; director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis; and medical oncologist, Siteman Cancer Center, discusses outcomes with catequentinib (Anlotinib) in the treatment of patients with synovial sarcoma. 

The randomized phase 3 APROMISS trial (NCT03016819) examined catequentinib vs dacarbazine in patients with advanced or metastatic synovial sarcoma. Because synovial sarcoma only represents approximately 10% of soft tissue sarcoma cases, and the study only enrolled those with advanced or metastatic disease who had undergone prior treatment with an anthracycline-based chemotherapy, the study population was very limited, according to Van Tine.

Results showed a progression-free survival benefit in patients treated with catequentinib compared with those who received dacarbazine. More importantly, it was found that prior treatment with pazopanib (Votrient) did not impact outcomes, Van Tine notes. This suggests that patients with synovial sarcoma may be able to receive treatment with multiple TKIs, Van Tine concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,